![\"Blue](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/03\/conceptual-shot-ozempic-glp-1-123981349.jpg\")
Novo Nordisk\u2019s patent on semaglutide, the active ingredient in drugs like Ozempic and Wegovy, is starting to expire around the globe. Shutterly \u2013 stock.adobe.com<\/p>\nThe weight-loss world is on the brink of a major shake-up.<\/p>\n
Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several other countries set to follow in the months ahead.<\/p>\n
The move is expected to unleash a wave of cheaper alternatives, dramatically widening access to the blockbuster diabetes and obesity treatments. <\/p>\n
Here\u2019s everything you need to know \u2014 including why Americans shouldn\u2019t start celebrating just yet.<\/p>\n
Novo Nordisk\u2019s patent on semaglutide, the active ingredient in drugs like Ozempic and Wegovy, is starting to expire around the globe. Shutterly \u2013 stock.adobe.com<\/p>\n
What\u2019s happening in India? <\/p>\n
Novo Nordisk\u2019s patent on semaglutide \u2014 the active ingredient in Ozempic and Wegovy \u2014 expires in India on Friday.\u00a0(Mounjaro and Zepbound are brand names for tirzepatide, a similar drug patented by Eli Lilly.)<\/p>\n
That will end the Danish drugmaker\u2019s monopoly on selling the drugs in the country, clearing the way for the first generic versions to hit the market as soon as this weekend.<\/p>\n
Right now, the drugs come with a hefty price tag<\/a>. Ozempic typically runs 8,800 to 11,000 rupees ($95\u2013$119) per month, while Wegovy can cost 10,000 to 16,000 rupees ($108\u2013$173), depending on the dose.<\/p>\n Indian generic makers haven\u2019t revealed their prices yet, but Reuters reports<\/a> they could be 50% to 60% cheaper. According to the New York Times<\/a>, analysts say they could eventually go for as little as $15 a month.<\/p>\n Which countries will get generics next?<\/p>\n Novo Nordisk\u2019s patents on semaglutide are set to expire in major markets around the world over the coming months. Generic versions are expected to roll out soon in China, Brazil, Turkey and South Africa.<\/p>\n The company\u2019s patent already expired<\/a> in Canada, but cheaper rivals aren\u2019t expected to hit pharmacies until mid-2026.<\/p>\n \u201cThe affordability that will come with generics and biosimilars will be hugely game-changing,\u201d Angie Jackson-Morris<\/a>, director of program development and strategy at the World Obesity Federation, told Bloomberg in January<\/a>.<\/p>\n Facing a wave of copycats, Novo Nordisk has already cut prices for Ozempic and Wegovy in India<\/a> and China<\/a>, aiming to hold its edge in the global diabetes and obesity markets.<\/p>\n Officials told the New York Times that the company is also exploring strategies to stay competitive in countries where generics will be available, including positioning the original drugs as a premium brand.<\/p>\n When will we get cheap generics for Ozempic and Wegovy in the US?<\/p>\n Americans will have to wait years before generic semaglutide hits the market. <\/p>\n Novo Nordisk will keep its patents on Ozempic and Wegovy in the US until 2032. It also holds exclusive rights in Japan and Europe until 2031, according to the company\u2019s 2024 earnings report<\/a>. <\/p>\n In the meantime, compounded \u2014 and often cheaper \u2014 versions of the drugs are available in the US, but they aren\u2019t FDA-approved generics and may carry additional safety risks<\/a>.<\/p>\n Can Americans import generic semaglutide from other countries?<\/p>\n In most cases, the answer is no. <\/p>\n It\u2019s illegal for Americans to import prescription drugs that haven\u2019t been approved by the Food and Drug Administration for use and sale in the US, according to Customs and Border Protection<\/a>.<\/p>\n That includes medications cleared by regulators abroad \u2014 like the generic versions expected to hit the market this weekend in India.<\/p>\n There are some limited exceptions. The FDA may allow personal importation in certain cases, such as for the treatment of a serious condition with no major safety concerns or when effective treatment isn\u2019t available in the US.<\/p>\n![\"The](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/03\/waving-flag-india-flag-poll-123981286_c032ca.jpg\")
Generic versions of Ozempic and Wegovy are expected to launch in India as soon as this weekend. charnsitr \u2013 stock.adobe.com<\/p>\n